Probing the free-state solution behavior of drugs and their tendencies to self-aggregate into nano-entities

Steven R. LaPlante, Valérie Roux, Fatma Shahout, Gabriela LaPlante, Simon Woo, Maria M. Denk, Sacha T. Larda, Yann Ayotte

Published: 2021-10-26 DOI: 10.1038/s41596-021-00612-3

nano-entities

drug self-assembly

NMR assays

dynamic light scattering

colloid characterization

AI 解读

In vitro reconstitution of COPII vesicles fromArabidopsis thalianasuspension-cultured cells

Anaerobic cryoEM protocols for air-sensitive nitrogenase proteins

Monomicellar assembly to synthesize structured and functional mesoporous carbonaceous nanomaterials

An optimized culture system for efficient derivation of porcine expanded potential stem cells from preimplantation embryos and by reprogramming somatic cells

Measuring DNA modifications with the comet assay: a compendium of protocols

Design and build of small-scale magnetic soft-bodied robots with multimodal locomotion

A practical guide to scanning light-field microscopy with digital adaptive optics

Reproducible mass spectrometry data processing and compound annotation in MZmine 3

Genetic in vivo engineering of human T lymphocytes in mouse models

Digital postprocessing and image segmentation for objective analysis of colorimetric reactions

查看全部

Sections

Figures

References

The free-state solution behaviors of drugs profoundly affect their properties. Therefore, it is critical to properly evaluate a drug’s unique multiphase equilibrium when in an aqueous enviroment, which can comprise lone molecules, self-associating
Introduction
Materials
Procedure
Troubleshooting
Anticipated results
- References
References
ACKNOWLEDGMENTS

LaPlante, S. R. et al. Monitoring drug self-aggregation and potential for promiscuity in off-target in vitro pharmacology screens by a practical nmr strategy. J. Med. Chem. 56, 7073–7083 (2013).
Duan, D. et al. Internal structure and preferential protein binding of colloidal aggregates. ACS Chem. Biol. 12, 282–290 (2017).
Feng, B. Y. & Shoichet, B. K. A detergent-based assay for the detection of promiscuous inhibitors. Nat. Protoc. 1, 550–553 (2006).
Feng, B. Y. et al. A high-throughput screen for aggregation-based inhibition in a large compound library. J. Med. Chem. 50, 2385–2390 (2007).
Owen, S. C., Doak, A. K., Wassam, P., Shoichet, M. S. & Shoichet, B. K. Colloidal aggregation affects the efficacy of anticancer drugs in cell culture. ACS Chem. Biol. 7, 1429–1435 (2012).
Dlim, M. M., Shahout, F. S., Khabir, M. K., Labonté, P. P. & Laplante, S. R. Revealing drug self-associations into nano-entities. ACS Omega 4, 8919–8925 (2019).
Ayotte, Y. et al. Exposing small-molecule nanoentities by a nuclear magnetic resonance relaxation assay. J. Med. Chem. 62, 7885–7896 (2019).
LaPlante, S. R. et al. Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists. J. Med. Chem. 56, 5142–5150 (2013).
Beaulieu, P. L. et al. Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: impact of lipophilicity on promiscuity and in vivo toxicity. Bioorg. Med. Chem. Lett. 25, 1140–1145 (2015).
Owen, S. C. et al. Colloidal drug formulations can explain ‘bell-shaped’ concentration-response curves. ACS Chem. Biol. 9, 777–784 (2014).
Tres, F., Posada, M. M., Hall, S. D., Mohutsky, M. A. & Taylor, L. S. The effect of promiscuous aggregation on in vitro drug metabolism assays. Pharm. Res. 36, 1–9 (2019).
Ganesh, A. N. et al. Colloidal drug aggregate stability in high serum conditions and pharmacokinetic consequence. ACS Chem. Biol. 14, 751–757 (2019).
Frenkel, Y. V. et al. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J. Med. Chem. 48, 1974–1983 (2005).
Frenkel, Y. V., Gallicchio, E., Das, K., Levy, R. M. & Arnold, E. Molecular dynamics study of non-nucleoside reverse transcriptase inhibitor 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile (TMC278/rilpivirine) aggregates: correlation between amphiphilic properties of the drug and oral bioavailability. J. Med. Chem. 52, 5896–5905 (2009).
Ganesh, A. N., Donders, E. N., Shoichet, B. K. & Shoichet, M. S. Collodial aggregation: from screening nuisance to formulation nuance. Nano Today 19, 188–200 (2018).
Hoo, C. M., Starostin, N., West, P. & Mecartney, M. L. A comparison of atomic force microscopy (AFM) and dynamic light scattering (DLS) methods to characterize nanoparticle size distributions. J. Nanopart. Res. 10, 89–96 (2008).
Tomaszewska, E. et al. Detection limits of DLS and UV-Vis spectroscopy in characterization of polydisperse nanoparticles colloids. J. Nanomater. 2013, 313081 (2013).
Akoka, S., Barantin, L. & Trierweiler, M. Concentration measurement by proton NMR using the ERETIC method. Anal. Chem. 71, 2554–2557 (1999).
Seidler, J., McGovern, S. L., Doman, T. N. & Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 46, 4477–4486 (2003).
Doak, A. K., Wille, H., Prusiner, S. B. & Shoichet, B. K. Colloid formation by drugs in simulated intestinal fluid. J. Med. Chem. 53, 4259–4265 (2010).
Hassan, P. A., Rana, S. & Verma, G. Making sense of Brownian motion: colloid characterization by dynamic light scattering. Langmuir 31, 3–12 (2015).
Ganesh, A. N., McLaughlin, C. K., Duan, D., Shoichet, B. K. & Shoichet, M. S. A new spin on antibody-drug conjugates: trastuzumab-fulvestrant colloidal drug aggregates target HER2-positive cells. ACS Appl. Mater. Interfaces 9, 12195–12202 (2017).
Wiest, J. et al. Geometrical and structural dynamics of imatinib within biorelevant colloids. Mol. Pharm. 15, 4470–4480 (2018).
Hong, Y., Lam, J. W. Y. & Tang, B. Z. Aggregation-induced emission. Chem. Soc. Rev. 40, 5361–5388 (2011).
Hong, Y., Lam, J. W. Y. & Tang, B. Z. Aggregation-induced emission: phenomenon, mechanism and applications. Chem. Comm. (29), 4332–4353 (2009).
Kestens, V., Bozatzidis, V., De Temmerman, P. J., Ramaye, Y. & Roebben, G. Validation of a particle tracking analysis method for the size determination of nano- and microparticles. J. Nanopart. Res. 19, 271 (2017).
Bevan, C. D. & Lloyd, R. S. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal. Chem. 72, 1781–1787 (2000).
Vom, A. et al. Detection and prevention of aggregation-based false positives in STD-NMR-based fragment screening. Aust. J. Chem. 66, 1518–1524 (2013).
Boulton, S. et al. Mechanisms of specific versus nonspecific interactions of aggregation-prone inhibitors and attenuators. J. Med. Chem. 62, 5063–5079 (2019).
Yang, Z. Y. et al. Structural analysis and identification of colloidal aggregators in drug discovery. J. Chem. Inf. Model. 59, 3714–3726 (2019).
Irwin, J. J. et al. An aggregation advisor for ligand discovery. J. Med. Chem. 58, 7076–7087 (2015).
Meiboom, S. & Gill, D. Modified spin-echo method for measuring nuclear relaxation times. Rev. Sci. Instrum. 29, 688–691 (1958).
Ryan, A. J., Gray, N. M., Lowe, P. N. & Chung, C. W. Effect of detergent on ‘promiscuous’ inhibitors. J. Med. Chem. 46, 3448–3451 (2003).
Feng, B. Y., Shelat, A., Doman, T. N., Guy, R. K. & Shoichet, B. K. High-throughput assays for promiscuous inhibitors. Nat. Chem. Biol. 1, 146–148 (2005).
Pellecchia, M., Sem, D. S. & Wüthrich, K. NMR in drug discovery. Nat. Rev. Drug Discov. 1, 211–219 (2002).
Hwang, J. & T., L. S. Water suppression that works. J. Magn. Reson. A 112, 275–279 (1995).

Probing the free-state solution behavior of drugs and their tendencies to self-aggregate into nano-entities

Extended

Supplementary information

推荐阅读